Products that Address Critical Applications
Caliper Life Sciences combines microfluidics, liquid handling and laboratory automation to deliver unique research tools for today’s Drug Discovery and Development and Genomics and Proteomics laboratories. We manufacture and sell products such as the LabChip 3000 Drug Discovery system, Caliper Sciclone liquid handler, Staccato Assay Workstations, and the LabChip 90 Automated Electrophoresis system. Each of these products addresses critical applications within the life sciences industry; each of these applications is on the critical path to improving human health.
Partnerships that Provide Real Solutions
In addition to our direct channel of business, Caliper seeks partnerships with premier life science companies, with the goal of permeating the life sciences and diagnostics industries with our proprietary microfluidics, liquid handling and automation technologies. The products of these collaborations benefit not just Caliper, but our partners, their customers, and the life sciences industry as a whole, as better approaches to experimentation and testing emerge.
In 2005, we acquired NovaScreen Biosciences. NovaScreen provides innovative drug discovery and development services that are designed to improve the productivity, accelerate the pace, and reduce the cost of pharmaceutical research and development. NovaScreen offers over 650 in vitro screening assays and assay development services to major pharmaceutical, biotechnology and educational institutions worldwide.
Beyond its core screening and assay development services, a leader in the secondary re-screening segment, NovaScreen also offers screening, pharmacological testing and database development to government agencies such as the National Institutes of Health (NIH), particularly the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute on Drug Abuse (NIDA). NovaScreen also offers a content database and pharmacoinformatics tool that provides statistical predictability in the drug discovery process.
NovaScreen’s business is operated in a facility located in Hanover, Maryland, from which it serves a customer base in the United States, Canada, Europe, Israel, India, Japan, South Korea and Australia. www.novascreen.com
Driving Adoption of Our Products and Technologies
A key part of our long-term strategy is driving adoption of our technologies, particularly our LabChip technologies and products in the life sciences industry. In our partnership channel, a number of new products have been brought to market by our partners: Agilent 2100 Bioanalyzer and 5100 Automated Lab-on-a-Chip system; Bio-Rad's Experion system, and Affymetrix' early-access GeneChip® target preparation systems. More recently, Affymetrix and Predicant Biosciences have licensed a portion of our microfluidics patent estate for use in proteomics and GeneChip analysis, respectively, under our "Caliper Driven" Program.
In our direct channel, we are seeing adoption of our LabChip 3000 screening and profiling system in major pharmaceutical companies worldwide, including Merck, Pfizer, J&J, Novartis, Sanofi-Aventis, Lilly, Wyeth, Takeda, Taisho, Serono, Amgen, and Millennium. The driving force behind the adoption momentum is the evolution of microfluidics technology from a research novelty to an enterprise discovery technology platform that can strategically transform the approach to discovering drugs. Caliper has produced a white paper that explains how the high-quality data and versatility of LabChip systems translates into a multitude of benefits for researchers.